Blog

Lockheed Martin, $5 million

United States, ex rel. John David Tillson, Natural Resources Defense Council, Inc., et al. v. Lockheed Martin Corp., et al., Western District of Kentucky. Lawyers with our firm represente...

Northwell Health, $12 million

United States of America ex rel. George Markelson, et. al. v. David B. Samadi, M.D. and Northwell Health, Inc. et al., Southern District of Florida. GBB attorneys represented one of three whi...

Humana Inc., $7 million

U.S., ex rel. Graves v. Plaza Med. Centers Corp., Humana Inc., and Michael Cavanaugh, Southern District of Florida. Our attorneys contributed to a qui tam action alleging that defendant Micha...

Bank of America, $95 million

U.S. ex rel. Szymoniak v. Bank of America, et al., District of South Carolina / Western District of North Carolina. Firm attorneys played a role in a False Claims Act recovery from mortgage s...

Amgen, $24.9 million

U.S. ex rel. Kurnik v. Amgen, Inc., et al., District of South Carolina. Firm attorneys represented Relator Frank Kurnik, in a case where pharmaceutical giant Amgen was alleged to have paid ki...

Pfizer (Rapamune), $257.4 million

U.S. ex rel. Sandler and Paris v. Wyeth Pharmaceuticals and Pfizer, Inc., Eastern District of Pennsylvania. The firm’s attorneys served as lead counsel for two whistleblowers who alleged mar...

Pfizer, $2.3 billion

U.S. ex rel. Demott v. Pfizer, District of Massachusetts. Firm attorneys represented one of six whistleblowers who revealed information to the government that resulted in an overall $2.3 bill...

GlaxoSmithKline, $1.04 billion

U.S. ex rel. Graydon v. GlaxoSmithKline, District of Massachusetts. Firm attorneys served as lead counsel for whistleblowers alleging that GlaxoSmithKline (GSK) engaged in illegal promotion o...

Community Health Systems, $97 million

U.S. ex rel. Doghramji, et al. v. Community Health Systems Inc., et al., Middle District of Tennessee. Firm attorneys represented three relators in a case alleging healthcare fraud by Tenness...

Abbott Labs, $1.6 billion

U.S. ex rel. McCoyd v. Abbott Laboratories, Western District of Virginia. The firm’s attorneys, in conjunction with state and federal governments, pursued claims against Abbot Laboratories, a...

Celgene Corporation, $280 million

U.S. ex rel. Brown v. Celgene Corporation, Central District of California. GBB recovered $280 million in a non-intervened False Claims Act case against Celgene Corporation on the eve of trial...

NITA Podcast: Best Practices for Remote Hearings

with Judge Amy Hanley and D.C. civil litigator Reuben Guttman to talk about how to get it right in video and telephonic hearings. In Episode 8 of the podcast, we are joined by Kansas Distri...

The Art of Opening Statements (Or Is It Opening Arguments?)

Getting a case down to its “gist” and to its “core,” retired federal judge Nancy Gertner said, involves picking the evidence that’s most favorable to your side. “That kind of selection is inevita...

False Claims Act Litigation: CLE

Program Date: June 22, 2020 | Over the last several years Americans have had a crash course in the role that whistleblowers play in compliance enforcement. No statute gives whistleblowers a g...

Whistleblowers Beware

By Reuben Guttman For fraudsters, government expenditures are a license to steal. One thing fraudsters know is that with trillions of dollars in expenditures from federal and state governments...

COVID-19 Will Lead to New False Claims Cases

The COVID-19 virus is inspiring new private-public relationships that will lead to a new generation of whistleblower cases under the Federal False Claims Act. Government is injecting billions...

False Claims Act: Offense and Defense

Description: Each year private citizen suits under the False Claims Act have returned billions of dollars to Federal and State treasuries. These suits leverage the government’s compliance en...
1 2 3 4 6